Abstract

BackgroundAlpha-1 antitrypsin deficiency (AATD) is a common, under-diagnosed disease caused by mutations in the polymorphic SERPINA1 gene. AATD is often causes chronic obstructive pulmonary disease (COPD), other respiratory ailments and/or severe liver disease. AATD under-diagnosis is associated with the lack of a quick, high precision test for SERPINA1 variants. Research QuestionCan a rapid and more accurate molecular diagnostic assay be developed that identifies AATD disease-associated mutations and outperforms current limited methodology? Study Design and MethodsWe developed a multiplexed PCR assay that that uses mass spectrometry to detect 20 pathogenic SERPINA1 mutations, two normal M allele variants and an additional variant of unknown significance, as an accessible frontline genetic test for AATD. Blood samples from 177 patients with AATD indication, 176 presumed normal genotype patients and 10 buccal swabs or blood spots were tested to validate the assay. Additionally, 760 whole blood samples from AATD indication patients were evaluated to identify AATD-associated mutations. ResultsThe novel genotyping assay described here accurately detected 23 SERPINA1 single nucleotide polymorphisms (SNPs) (“AAT SNP23”). Of 177 AATD samples, 96% had abnormal SNPs, whereas 9.1% of the 176 presumed normal samples had abnormal SNPs. AAT SNP23 genotypes correlated well with known serum AAT levels. This genotyping assay was more accurate and streamlined than phenotyping isoelectric focusing assay used to identify AATD variants. For clinical testing, serum AAT protein level determination and AAT SNP23 genotyping assay were performed. AAT SNP23 was successfully implemented using AATD indication patient samples to evaluate the most common SERPINA1 mutations indicative of AATD. AAT SNP23 has allowed for quick and accurate AAT genotyping of patients. InterpretationWe developed a novel, multiplexed genotyping assay that rapidly and accurately identifies multiple AATD-associated SERPINA1 SNPs. This assay is useful to quickly diagnose AATD in patients with pulmonary and/or hepatic diseases of unknown etiology.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.